ENDPOINTS NEWS20m
Aclaris makes a deal, aims to raise $80M; Em­me­cell’s Ph1 up­date in corneal ede­ma
Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...
ENDPOINTS NEWS1h
At­las Ven­ture tar­gets $450M for 14th biotech fund, the same size as its 2022 raise
At­las Ven­ture, one of biotech’s go-to VC firms, is eye­ing a $450 mil­lion 14th fund, part­ner Bruce Booth said in its ...
ENDPOINTS NEWS3h
Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...
ENDPOINTS NEWS3h
Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds
San Diego biotech Aven­zo Ther­a­peu­tics has in-li­censed an­oth­er as­set, this time se­cur­ing the glob­al ex-Chi­na ...
ENDPOINTS NEWS3h
Cy­bin says its psy­che­del­ic drug can sus­tain re­mis­sion in de­pres­sion pa­tients
Cy­bin said its psilocin ana­log has the po­ten­tial to wipe out symp­toms in most pa­tients with a se­ri­ous form of ...
ENDPOINTS NEWS4h
Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?
Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...
ENDPOINTS NEWS6h
In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set
In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...
ENDPOINTS NEWS8h
Ex­clu­sive: Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...